MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation
2015 (English)In: Allergy. European Journal of Allergy and Clinical Immunology, ISSN 0105-4538, E-ISSN 1398-9995, Vol. 70, no 11, 1372-1392 p.Article in journal (Refereed) Published
Several unmet needs have been identified in allergic rhinitis: identification of the time of onset of the pollen season, optimal control of rhinitis and comorbidities, patient stratification, multidisciplinary team for integrated care pathways, innovation in clinical trials and, above all, patient empowerment. MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) is a simple system centred around the patient which was devised to fill many of these gaps using Information and Communications Technology (ICT) tools and a clinical decision support system (CDSS) based on the most widely used guideline in allergic rhinitis and its asthma comorbidity (ARIA 2015 revision). It is one of the implementation systems of Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA). Three tools are used for the electronic monitoring of allergic diseases: a cell phone-based daily visual analogue scale (VAS) assessment of disease control, CARAT (Control of Allergic Rhinitis and Asthma Test) and e-Allergy screening (premedical system of early diagnosis of allergy and asthma based on online tools). These tools are combined with a clinical decision support system (CDSS) and are available in many languages. An e-CRF and an e-learning tool complete MASK. MASK is flexible and other tools can be added. It appears to be an advanced, global and integrated ICT answer for many unmet needs in allergic diseases which will improve policies and standards.
Place, publisher, year, edition, pages
WILEY-BLACKWELL , 2015. Vol. 70, no 11, 1372-1392 p.
allergic rhinitis; ARIA; asthma; Information and communications technology; MACVIA-LR
IdentifiersURN: urn:nbn:se:liu:diva-122775DOI: 10.1111/all.12686ISI: 000363329400003PubMedID: 26148220OAI: oai:DiVA.org:liu-122775DiVA: diva2:876693
Funding Agencies|Chiesi; GSK; Cipla; Sanofi/Regeneron; Novartis; Circassia; Merck; Stallergenes; Medical Research Council; JP Moulton Charitable Foundation; North West Lung Research Centre Charity; European Union; National Institute of Health Research; Thermo Fisher; AstraZeneca; ALK; GlaxoSmithKline; ALK Abello; Merck USA; Biomay; Leti; Biotech Tools; A. Menarini; Aerocrine; Merck Sharp Dohme; Teva; Boehringer Ingelheim; MSD; OrionPharma; Centocor; Sanofi Pasteur; Grunenthal; Synairgen; Stallergens; ALK Abello (Germany/Denmark); Allergopharma (Germany); Stallergenes (Germany/France); HAL Allergy (Germany/the Netherlands); Artu Biologicals (the Netherlands); Allergy Therapeutics/Bencard (UK/Germany); Hartington (Spain); Lofarma (Italy); Novartis/Leti (Germany/Spain); GlaxoSmithKline (UK/Germany); Essex Pharma (Germany); Cytos (Switzerland); Curalogic (Denmark); Roxall (Germany); Biomay (Austria); Thermo Fisher (Germany); Circassia (UK); Biotech Tools s.a. (Belgium); Meda Pharma GmbH (Germany); HAL Allergy (the Netherlands/Germany); Meda (Germany/Sweden); Dutch Lung Foundation; Ubbo Emmius Foundation; Stichting Astma Bestrijding; Adamed; Allergopharma; Almirall; Celon Pharma; FAES; HAL; Meda; Pfizer; Polfarmex; Polpharma; Stallergen; Lekam; UCB; Sanofi; Carnot; Senosiain; Almirral; Jansen; Pearl; Roche; AZ; Astellas; Genentech; Uriach; Abbott Laboratories; ALK-Abello; Ohropax; Servier; Stada; Menarini; Allergy Therapeutics; Bayer; Johnson+ Johnson; Arthrocare; Bencard; BiotechTools; Lofarma; Ursapharm; Bitop; AIPreven; Optima; Torii Co. Ltd.; Shionogi Co. Ltd.; MSD Co. LtD; Tanabe-Mitsubishi; Ono; Taiho; Torii; Kyowa-Kirin; Guidotti-Malesci; Mundipharma; Takeda; Zambon; Chiesi Farmaceutici; Merck Sharp Dohme; DGAKI; GlaxoSmithKline (Germany); Bencard (Germany); Novartis (Germany); Ministry of Science, Education and Sports of Republic of Croatia; Sandoz; Salveo; Schering-Plough; UK National Health Service; British Lung Foundation; AKL Ltd; Eli Lilly; Napp; Orion; Respiratory Effectiveness Group; Zentiva; Efficacy and Mechanism Evaluation programme; HTA; Novartis Farma; Faes Farma; Bial Aristegui; Boehringer; Biomay AG; Vienna, Austria; Uppsala, Sweden2015-12-042015-11-232016-03-09